Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I

A multitude of TKI has been developed and approved targeting various oncogenetic alterations. While these have provided improvements in efficacy compared with conventional chemotherapies, resistance to targeted therapies occurs. Mutations in the kinase domain result in the inability of TKI to inacti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Critical reviews in oncology/hematology 2024-07, Vol.199, p.104384, Article 104384
Hauptverfasser:	Combarel, David, Dousset, Léa, Bouchet, Stéphane, Ferrer, Florent, Tetu, Pauline, Lebbe, Céleste, Ciccolini, Joseph, Meyer, Nicolas, Paci, Angelo
Format:	Artikel
Sprache:	eng
Schlagworte:	BRAF Life Sciences Melanoma Pharmacodynamic Pharmacokinetic Santé publique et épidémiologie Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!